QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO) Leverages Powerful Stem Cell Technology To Advance Regenerative Medicine 0 comments
    Jan 6, 2014 10:35 AM | about stocks: ISCO

    International Stem Cell is a biotechnology company leveraging powerful new stem cell technology called parthenogenesis, which uses unfertilized eggs to advance the field of regenerative medicine. The company is focusing its use of these cells to treat diseases of the eye, nervous system, and liver.

    Cell therapy for these indications has been proven clinically. However, therapeutic options are limited by the availability of safe, immune-matched human cells or tissue. To address this issue and avoid immune-rejection, International Stem Cell is pioneering the development of a new class of stem cells called human parthenogenetic stem cells (hpSCs), which demonstrate the superior characteristics of other classes of stem cells.

    hpSCs are created by chemical stimulation of unfertilized human eggs to begin division - it's important to note that no viable embryo is created or destroyed in this process. International Stem Cell recently was recognized for its advances toward the treatment of liver disease based on its hpSC technology.

    The company, in December 2013, was awarded the Presidential Poster of Distinction by the American Association for the Study of Liver Disease (AASLD) at the 64th Annual Liver Meeting in Washington, D.C. The data presented at the conference demonstrated that transplantation of hpSC-derived hepatocytes cells (HLCs) in a pre-clinical study resulted in a significant decrease and long-term stabilization of bilirubin levels in the serum of Gunn rats, a well-established animal model of Crigler-Najjar syndrome type 1 (CN1), a rare and inherited liver-based metabolic disorder. In the four months following treatment, no adverse safety signals were detected.

    Moving forward, International Stem Cell continues to advance its technology pipeline to demonstrate the revolutionary nature of its HLCs and their potential efficacy for the company's stated indications.

    For more information, visit internationalstemcell.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.